RBFC
ABMD

Roman Butler Fullerton & Co’s Abiomed Inc ABMD Stock Holding History

Roman Butler Fullerton & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,682
Closed -$480K – 181
2019
Q1 		$480K Sell
1,682
-748
-31% -$249K 0.34% 105
2018
Q4 		$814K Buy
+2,430
New +$844K 0.69% 48

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Roman Butler Fullerton & Co's ABMD Position: Q2 2019 in Review

Roman Butler Fullerton & Co sold out of Abiomed Inc (ABMD) in Q2 2019, closing a stake of 1,682 shares — an estimated $480K sold.

Roman Butler Fullerton & Co first reported a position in ABMD in Q4 2018 and held it in 2 quarters. The position peaked at $814K in Q4 2018. 484 funds tracked by Wall St. Rank hold ABMD as of Q2 2019.

  • Roman Butler Fullerton & Co reported no remaining Abiomed Inc position as of Q2 2019 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 1,682 Abiomed Inc shares in Q2 2019, an estimated $480K.
  • Roman Butler Fullerton & Co first reported a position in Abiomed Inc in Q4 2018 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Abiomed Inc position peaked at $814K in Q4 2018.
  • 484 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2019.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2019, filed 22 Jul 2019.